100 Bayer Road
It all starts with a friendship between two men, plenty of natural curiosity and two kitchen stoves. Businessman Friedrich Bayer and dyer Johann Friedrich Weskott use these to conduct experiments and eventually discover how to make the dye fuchsine.
On August 1, 1863, they found the "Friedr. Bayer et. comp." company in Wuppertal-Barmen, a 19th century startup with tremendous potential.
Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time.
Our goal is to create value for our customers, stockholders and employees, while also strengthening the company’s earning power. We are committed to operating sustainably and addressing our social and ethical responsibilities. Employees with a passion for innovation enjoy excellent development opportunities at Bayer.
All this goes to make up our purpose: Science for a better life.
Passion to innovate | Power to change
531 articles with Bayer
Bayer's Stivarga® (regorafenib) becomes first compound used in clinical trial platform to investigate new therapies for brain cancer
Bayer announced today that the Stivarga® (regorafenib) arm of the platform trial GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) has opened enrollment for patients with newly diagnosed and recurrent glioblastoma, the most aggressive and common form of primary brain cancer
New partnership to provide journalists with educational resources, grants and scholarships
Esplanade® 200 SC herbicide Emergency Exemption is in place for Montana, Wyoming and Utah
The two companies will pair CStone’s CS1001 with Bayer’s regorafenib, an oral multi-kinase inhibitor that targets VEGFR, FGFR, CSF1R and other receptors.
Bayer and Arvinas, Inc. to develop novel Proteolysis-Targeting Chimera candidates for humans and plants
Bayer announced a collaboration with Arvinas, Inc., a biopharmaceutical company based in New Haven, Connecticut.
As the American Society of Clinical Oncology Annual Meeting winds down, here’s a look at some of Monday’s top stories.
New data on Vitrakvi® (larotrectinib) in TRK fusion cancer patients with brain metastases or primary central nervous system (CNS) tumors
Bayer today announced results of a new analysis from clinical trials investigating Vitrakvi® (larotrectinib) in patients with TRK fusion cancer with primary central nervous system (CNS) tumors or brain metastases.
Bayer Receives U.S. FDA Breakthrough Therapy Designation for Aliqopa™ (copanlisib) for the Treatment of Marginal Zone Lymphoma
Bayer announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for Aliqopa™ for the treatment of adult patients with relapsed marginal zone lymphoma who have received at least two prior therapies.
Sensible Medical Innovations and Bayer successfully signed an agreement making Bayer, Sensible's largest customer in Europe.
In addition to education and training, it will offer Bayer’s complete portfolio of recombinant Factor VIII treatments to healthcare providers in more than 60 countries.
Bayer Launches Pulmonary Hypertension Accelerated Bayer (PHAB) Awards to Help Propel Clinical Advancements Forward with up to 1 Million Dollars in Grants
The PHAB Awards to be one of the largest industry-funded grant programs focused on pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Bayer presents new analyses for Vitrakvi® (larotrectinib) in adult and pediatric patients with TRK fusion cancer with solid tumors, and new data in primary central nervous system tumors and brain metastases
Bayer announced findings from new analyses and data for Vitrakvi®, which is approved for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tropomyosin receptor kinase gene fusion without a known acquired resistance mutation that are either metastatic or where surgical resection will likely result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.
Investment Announced at Patriot Elementary as part of a Salad Bar Donation Ceremony and Carrot Variety Taste Test
Bayer said the award conflicts with an April report from the EPA that says glyphosate, the active ingredient in Roundup, is not a carcinogen.
Bayer released the following statement in reaction to a jury verdict in favor of the plaintiffs in the case of Pilliod v. Monsanto, a trial conducted before Judge Winifred Smith in the Superior Court of the State of California for the County of Alameda.
Bayer will present research from its expanding oncology portfolio at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019, taking place May 31 to June 4 in Chicago.
Divya Annamraju, Deputy Director of Strategy for Medical Devices Product Supply at Bayer, Honored as Healthcare Businesswomen's Association Luminary
Divya Annamraju, Deputy Director of Strategy for Medical Devices Product Supply at Bayer, was honored as a Luminary by the Healthcare Businesswomen's Association at its annual Woman of the Year event, Thursday, May 9, at the Marriott Marquis in New York.
Bayer plans to build a Cell Culture Technology Center in Berkeley, Calif., investing $150 million in the project. The center will focus on developing biologics, an area where Bayer lags behind its competitors.
Fluor and Bayer Break Ground as Construction Starts for New Cell Culture Technology Center in California
Fluor Corporation announced that a groundbreaking event was held today for Bayer’s first-of-a-kind cell culture technology center in Berkeley, California.
Bayer Invests $150 Million to Build New Cell Culture Technology Center in Berkeley to Spur Innovation of Biotech Therapies
New development facility reflects continued commitment to California Bay Area